136 related articles for article (PubMed ID: 8427867)
1. Lipoproteins in familial dysbetalipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration.
Zhao SP; Smelt AH; Leuven JA; van den Maagdenberg AM; van der Laarse A; van 't Hooft FM
Arterioscler Thromb; 1993 Feb; 13(2):316-23. PubMed ID: 8427867
[TBL] [Abstract][Full Text] [Related]
2. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
3. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) compared.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Van der Laarse A; Van 't Hooft FM
Clin Chem; 1994 Aug; 40(8):1559-66. PubMed ID: 8044997
[TBL] [Abstract][Full Text] [Related]
5. Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
Schmitz G; Assmann G; Augustin J; Dirkes-Kersting A; Brennhaüsen B; Karoff C
J Lipid Res; 1985 Mar; 26(3):316-26. PubMed ID: 3989390
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
7. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein.
Sattar N; Greer IA; Louden J; Lindsay G; McConnell M; Shepherd J; Packard CJ
J Clin Endocrinol Metab; 1997 Aug; 82(8):2483-91. PubMed ID: 9253322
[TBL] [Abstract][Full Text] [Related]
9. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
Chappell DA
J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
[TBL] [Abstract][Full Text] [Related]
10. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
11. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.
Dallongeville J; Boulet L; Davignon J; Lussier-Cacan S
Arterioscler Thromb; 1991; 11(4):864-71. PubMed ID: 2065040
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
13. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Mackness M
Arterioscler Thromb; 1992 Aug; 12(8):920-8. PubMed ID: 1637789
[TBL] [Abstract][Full Text] [Related]
15. An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein.
Koba S; Hirano T; Sakaue T; Takeuchi H; Adachi M; Katagiri T
Coron Artery Dis; 2002 Aug; 13(5):255-62. PubMed ID: 12394649
[TBL] [Abstract][Full Text] [Related]
16. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
[TBL] [Abstract][Full Text] [Related]
17. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype.
Todo Y; Kobayashi J; Higashikata T; Kawashiri M; Nohara A; Inazu A; Koizumi J; Mabuchi H
Clin Chim Acta; 2004 Oct; 348(1-2):35-40. PubMed ID: 15369733
[TBL] [Abstract][Full Text] [Related]
18. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
Georgieva AM; van Greevenbroek MM; Krauss RM; Brouwers MC; Vermeulen VM; Robertus-Teunissen MG; van der Kallen CJ; de Bruin TW
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
[TBL] [Abstract][Full Text] [Related]
19. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
Taskinen MR; Packard CJ; Shepherd J
Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
[TBL] [Abstract][Full Text] [Related]
20. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
Agheli N; Cloarec M; Jacotot B
Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
